FY2025 Earnings Forecast for CNTA Issued By Chardan Capital

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a research note issued on Wednesday, November 19th. Chardan Capital analyst K. Nakae forecasts that the company will earn ($1.50) per share for the year. Chardan Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Chardan Capital also issued estimates for Centessa Pharmaceuticals’ FY2026 earnings at ($1.45) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02).

Several other research firms also recently issued reports on CNTA. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. Guggenheim lifted their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Stephens started coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 target price on the stock. Lifesci Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Finally, Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $34.78.

Centessa Pharmaceuticals Trading Down 1.4%

Centessa Pharmaceuticals stock opened at $28.96 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock has a market cap of $3.89 billion, a PE ratio of -15.83 and a beta of 1.56. The stock has a 50-day moving average of $24.13 and a two-hundred day moving average of $18.32. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $29.90.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC boosted its holdings in Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after buying an additional 5,808,080 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Centessa Pharmaceuticals by 35.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock valued at $99,999,000 after buying an additional 1,834,973 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth about $42,429,000. Balyasny Asset Management L.P. purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth about $16,052,000. Finally, Commodore Capital LP grew its position in shares of Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after acquiring an additional 930,711 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $22.41, for a total transaction of $134,460.00. Following the completion of the transaction, the general counsel owned 105,386 shares in the company, valued at approximately $2,361,700.26. This trade represents a 5.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mario Alberto Accardi sold 8,000 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the completion of the sale, the insider owned 194,394 shares in the company, valued at $4,859,850. The trade was a 3.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 179,964 shares of company stock valued at $4,106,481. Company insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.